Hologic (HOLX) Receives a Hold from Leerink Partners

In a report released today, Richard Newitter from Leerink Partners maintained a Hold rating on Hologic (HOLX), with a price target of $41.00. The company’s shares closed last Wednesday at $38.54.

According to TipRanks.com, Newitter is a top 100 analyst with an average return of 22.4% and a 65.9% success rate. Newitter covers the Healthcare sector, focusing on stocks such as Zimmer Biomet Holdings, Becton Dickinson, and Globus Medical.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Hologic with a $49.00 average price target, which is a 31.3% upside from current levels. In a report issued on March 27, Morgan Stanley also upgraded the stock to Hold with a $40.00 price target.

See today’s analyst top recommended stocks >>

Based on Hologic’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $851 million and net profit of $386 million. In comparison, last year the company earned revenue of $831 million and had a net profit of $98.6 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Hologic, Inc. engages in the development, manufacture, and supply of diagnostics products, medical imaging systems, and surgical products dedicated to serve the healthcare needs of women. It operates through the following business segments: Breast Health, Diagnostics, Medical Aesthetics, GYN Surgical, and Skeletal Health. The Breast Health segment includes a broad portfolio of breast imaging and related products and accessories, including digital mammography systems, computer-aided detection, for mammography and minimally invasive breast biopsy devices, breast biopsy site markers, and breast biopsy guidance systems. The Diagnostics segment comprises Aptima family of Assays, target capture/nucleic acid extraction techonolgy, transcription-mediated amplification technology, hybridization protection assay and dual kinetic assat technologies, instrumentation, and Invader Chemistry Platform. The Medical Aesthetics segment offers SculpSure; PicoSure, MedLite, and RevLite; and MonaLisa Touch. The GYN Surgical segment encompasses the NovaSure Endometrial Ablation System and the MyoSure Hysteroscopic Tissue Removal System. The Skeletal Health segment covers the discovery and horizon X-ray bone densitometry system, an ultrasound-based osteoporosis assessment product, and Fluoroscan mini C-arm imaging products. The company was founded by S. David Ellenbogen and Jay A. Stein in 1986 and is headquartered in Marlborough, MA.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts